Neuronal Interfaces in Bioelectronic Medicines for Unlocking Therapeutic Potential for ANS Issues

Bioelectronic devices that alter autonomic nervous system (ANS) activity to treat a variety of disorders have been made possible by developments in neurotechnology, micro/nano-engineering, and biocompatible materials. The paper discusses preclinical and clinical applications, emphasises advancements in electrode technology, and tackles issues including neuromodulation processes and patient-specific requirements. By using developments in neurotechnology, micro/nano-engineering, and biocompatible materials, the present work explores how bioelectronic devices may be able to modify ANS activity in order to cure a variety of illnesses.

The study looks at preclinical and clinical uses, demonstrates electrode technology developments, and assesses how well they work to treat metabolic, inflammatory, cardiovascular, and pelvic conditions.

There are difficulties in addressing patient-specific demands, standardising procedures, and comprehending neuromodulation processes. In order to broaden the therapeutic reach of BM, future approaches will prioritise integrative research and technology advancements.

Neuronal interfaces in bioelectronic medicine enable precise neuromodulation of the autonomic nervous system (ANS), offering targeted therapies for disorders like inflammation, hypertension, and GI dysmotility. Key results show clinical successes such as vagus nerve stimulation (VNS) reducing inflammatory cytokines in rheumatoid arthritis and improving metabolic control in diabetes. Chronic implantation triggers foreign body response and glial scarring, degrading signals over months. Few large-scale ANS-specific trials exist, with most data preclinical or from related CNS applications.

A few case studies are summarized in the manuscript, highlighting the use of bioelectronic medicines in Autonomic disorders.